Reipet – Lifestyle
Author:
ALX Oncology
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
May 7, 2026
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
April 30, 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
April 17, 2026
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
April 13, 2026